The Function of SPARC as a Mediator of Fibrosis

Fibrosis is a common end-point of a number of different diseases such as hypertension, diabetes, liver cirrhosis, and those associated with chronic inflammation. Fibrosis is characterized by excessive deposition of extracellular matrix that interferes with normal tissue architecture and function. Increased expression of secreted protein acidic and rich in cysteine (SPARC) in fibrotic tissues has been reported in numerous studies. SPARC is a 43 kDa collagen-binding protein secreted from several different cell types into the extracellular matrix and has been shown to be anti-proliferative and counter-adhesive in vitro. SPARC is a matricellular protein; meaning SPARC is secreted into the extracellular space but does not serve a structural function. Instead, SPARC modulates interactions between cells and the surrounding extracellular matrix. In animal models of fibrotic disease and in human fibrotic tissues, elevated expression of SPARC has been reported in many tissues including heart, lungs, kidneys, liver, dermis, intestine, and eyes. In this review, we will summarize current studies that have examined the expression and functional importance of SPARC in various animal models of fibrosis and in human tissues. Although cellular mechanisms of SPARC in fibrosis remain to be fully elucidated, the studies summarized here provide impetus to further explore the efficacy of SPARC as a potential target for reducing fibrosis.

[1]  T. Wong,et al.  In vitro analyses of the anti-fibrotic effect of SPARC silencing in human Tenon’s fibroblasts: comparisons with mitomycin C , 2012, Journal of cellular and molecular medicine.

[2]  M. Colombo,et al.  SPARC oppositely regulates inflammation and fibrosis in bleomycin-induced lung damage. , 2011, The American journal of pathology.

[3]  O. Podhajcer,et al.  SPARC promotes cathepsin B-mediated melanoma invasiveness through a collagen I/α2β1 integrin axis. , 2011, The Journal of investigative dermatology.

[4]  R. Brekken,et al.  SPARC regulates collagen interaction with cardiac fibroblast cell surfaces. , 2011, American journal of physiology. Heart and circulatory physiology.

[5]  J. Ampuero,et al.  Sentinel Surveillance of Influenza-Like-Illness in Two Cities of the Tropical Country of Ecuador: 2006–2010 , 2011, PloS one.

[6]  R. Brekken,et al.  The regulatory function of SPARC in vascular biology , 2011, Cellular and Molecular Life Sciences.

[7]  R. Brekken,et al.  SPARC promotes pericyte recruitment via inhibition of endoglin-dependent TGF-b1 activity , 2011 .

[8]  R. Brekken,et al.  SPARC promotes pericyte recruitment via inhibition of endoglin-dependent TGF-β1 activity , 2011, The Journal of cell biology.

[9]  S. Friedman,et al.  SPARC downregulation attenuates the profibrogenic response of hepatic stellate cells induced by TGF-β1 and PDGF. , 2011, American journal of physiology. Gastrointestinal and liver physiology.

[10]  C. Rossa,et al.  LPS Induces Greater Bone and PDL Loss in SPARC-null Mice , 2011, Journal of dental research.

[11]  H. Chapman,et al.  Epithelial-mesenchymal interactions in pulmonary fibrosis. , 2011, Annual review of physiology.

[12]  M. Le Hir,et al.  Epithelial-mesenchymal transition (EMT) in kidney fibrosis: fact or fantasy? , 2011, The Journal of clinical investigation.

[13]  A. Jünemann,et al.  SPARC is expressed in scars of the Tenon’s capsule and mediates scarring properties of human Tenon’s fibroblasts in vitro , 2011, Molecular vision.

[14]  A. Bradshaw,et al.  SPARC/Osteonectin Functions to Maintain Homeostasis of the Collagenous Extracellular Matrix in the Periodontal Ligament , 2010, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[15]  F. Arnett,et al.  Attenuation of fibrosis in vitro and in vivo with SPARC siRNA , 2010, Arthritis research & therapy.

[16]  S. Heymans,et al.  Cardiac extracellular matrix remodeling: fibrillar collagens and Secreted Protein Acidic and Rich in Cysteine (SPARC). , 2010, Journal of molecular and cellular cardiology.

[17]  T. Aung,et al.  SPARC Deficiency Results in Improved Surgical Survival in a Novel Mouse Model of Glaucoma Filtration Surgery , 2010, PloS one.

[18]  M. Zile,et al.  Age-dependent alterations in fibrillar collagen content and myocardial diastolic function: role of SPARC in post-synthetic procollagen processing. , 2010, American journal of physiology. Heart and circulatory physiology.

[19]  S. Cohn,et al.  Modulation of matrix remodeling by SPARC in neoplastic progression. , 2010, Seminars in cell & developmental biology.

[20]  G. Rosen,et al.  SPARC Suppresses Apoptosis of Idiopathic Pulmonary Fibrosis Fibroblasts through Constitutive Activation of β-Catenin* , 2010, The Journal of Biological Chemistry.

[21]  E. Hohenester,et al.  Crystallographic Insight into Collagen Recognition by Discoidin Domain Receptor 2 , 2009, Structure.

[22]  R. Durvasula,et al.  SPARC accelerates disease progression in experimental crescentic glomerulonephritis. , 2009, The American journal of pathology.

[23]  J. Lacy,et al.  Pressure Overload–Induced Alterations in Fibrillar Collagen Content and Myocardial Diastolic Function: Role of Secreted Protein Acidic and Rich in Cysteine (SPARC) in Post–Synthetic Procollagen Processing , 2009, Circulation.

[24]  Takako Sasaki,et al.  Structural basis of sequence-specific collagen recognition by SPARC , 2008, Proceedings of the National Academy of Sciences.

[25]  O. Podhajcer,et al.  Adenovirus‐mediated inhibition of SPARC attenuates liver fibrosis in rats , 2008, The journal of gene medicine.

[26]  E. Sage,et al.  The Copper Binding Domain of SPARC Mediates Cell Survival in Vitro via Interaction with Integrin β1 and Activation of Integrin-linked Kinase* , 2008, Journal of Biological Chemistry.

[27]  I. Lawrance,et al.  Indomethacin and Retinoic Acid Modify Mouse Intestinal Inflammation and Fibrosis: A Role for SPARC , 2008, Digestive Diseases and Sciences.

[28]  P. Bornstein,et al.  SPARC Regulates Processing of Procollagen I and Collagen Fibrillogenesis in Dermal Fibroblasts* , 2007, Journal of Biological Chemistry.

[29]  F. Arnett,et al.  Attenuation of collagen production with small interfering RNA of SPARC in cultured fibroblasts from the skin of patients with scleroderma. , 2006, Arthritis and rheumatism.

[30]  William P Schiemann,et al.  SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system. , 2003, Molecular biology of the cell.

[31]  J. Davidson,et al.  SPARC-null mice display abnormalities in the dermis characterized by decreased collagen fibril diameter and reduced tensile strength. , 2003, The Journal of investigative dermatology.

[32]  E. Sage,et al.  SPARC-null mice exhibit increased adiposity without significant differences in overall body weight , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[33]  C. Alpers,et al.  Amelioration of diabetic nephropathy in SPARC-null mice. , 2003, Journal of the American Society of Nephrology : JASN.

[34]  D. Arking,et al.  Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome , 2003, Nature Genetics.

[35]  C. Alpers,et al.  Localization of SPARC in developing, mature, and chronically injured human allograft kidneys. , 2002, Kidney international.

[36]  R. Macko,et al.  Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activation. , 2002, The Journal of rheumatology.

[37]  P. Bornstein,et al.  Matricellular proteins: extracellular modulators of cell function. , 2002, Current opinion in cell biology.

[38]  S. Seki,et al.  Expression of SPARC by activated hepatic stellate cells and its correlation with the stages of fibrogenesis in human chronic hepatitis , 2002, Virchows Archiv.

[39]  R. Savani,et al.  Bleomycin-induced pulmonary injury in mice deficient in SPARC. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[40]  K. Dohi,et al.  Secreted protein acidic and rich in cysteine (SPARC) in patients with diabetic nephropathy and tubulointerstitial injury , 2000, Diabetologia.

[41]  M. Amling,et al.  Osteopenia and decreased bone formation in osteonectin-deficient mice , 2000, The Journal of clinical investigation.

[42]  W. Couser,et al.  SPARC Regulates the Expression of Collagen Type I and Transforming Growth Factor-β1 in Mesangial Cells* , 1999, The Journal of Biological Chemistry.

[43]  E. Sage,et al.  Collagen accumulation is decreased in SPARC-null mice with bleomycin-induced pulmonary fibrosis. , 1999, American journal of physiology. Lung cellular and molecular physiology.

[44]  E. Sage,et al.  SPARC deficiency leads to early-onset cataractogenesis. , 1998, Investigative ophthalmology & visual science.

[45]  R. Timpl,et al.  Crystal structure and mapping by site‐directed mutagenesis of the collagen‐binding epitope of an activated form of BM‐40/SPARC/osteonectin , 1998, The EMBO journal.

[46]  A. Hendrickson,et al.  SPARC Is Expressed by Ganglion Cells and Astrocytes in Bovine Retina , 1998, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[47]  K. Okubo,et al.  Osteonectin (SPARC) expression in human liver and in cultured human liver myofibroblasts. , 1997, The American journal of pathology.

[48]  M. Cooper,et al.  Secreted protein acidic and rich in cysteine expression after subtotal nephrectomy and blockade of the renin-angiotensin system. , 1997, Journal of the American Society of Nephrology : JASN.

[49]  M. Reed,et al.  SPARC is expressed in renal interstitial fibrosis and in renal vascular injury. , 1996, Kidney international.

[50]  M. Reed,et al.  SPARC is expressed by mesangial cells in experimental mesangial proliferative nephritis and inhibits platelet-derived-growth-factor-medicated mesangial cell proliferation in vitro. , 1996, The American journal of pathology.

[51]  R. Mason,et al.  Immunolocalization of SPARC, tenascin, and thrombospondin in pulmonary fibrosis. , 1995, The American journal of pathology.

[52]  L. Malaval,et al.  SPARC, an extracellular matrix glycoprotein containing the follistatin module, is expressed by astrocytes in synaptic enriched regions of the adult brain , 1995, Brain Research.

[53]  M. Eghbali,et al.  Expression of SPARC in normal and fibrotic livers , 1995, Hepatology.

[54]  G. Webersinke,et al.  Comparison of gene expression of extracellular matrix molecules in brain microvascular endothelial cells and astrocytes. , 1992, Biochemical and biophysical research communications.

[55]  J. Wrana,et al.  Regulation of the expression of a secreted acidic protein rich in cysteine (SPARC) in human fibroblasts by transforming growth factor beta. Comparison of transcriptional and post-transcriptional control with fibronectin and type I collagen. , 1991, European journal of biochemistry.

[56]  E. Vuorio,et al.  Expression of osteonectin, decorin, and transforming growth factor-beta 1 genes in fibroblasts cultured from patients with systemic sclerosis and morphea. , 1991, The Journal of rheumatology.

[57]  E. A. Everitt,et al.  SPARC, a secreted protein associated with cellular proliferation, inhibits cell spreading in vitro and exhibits Ca+2-dependent binding to the extracellular matrix , 1989, The Journal of cell biology.

[58]  S. Funk,et al.  SPARC: a Ca2+-binding extracellular protein associated with endothelial cell injury and proliferation. , 1989, Journal of molecular and cellular cardiology.

[59]  P. Holland,et al.  In vivo expression of mRNA for the Ca++-binding protein SPARC (osteonectin) revealed by in situ hybridization , 1987, The Journal of cell biology.

[60]  A. Schulz,et al.  Osteonectin — a differentiation marker of bone cells , 1987, Cell and Tissue Research.

[61]  G. Riemekasten,et al.  Systemic sclerosis - a systematic overview: part 2 - immunosuppression, treatment of SSc-associated vasculopathy, and treatment of pulmonary arterial hypertension. , 2011, VASA. Zeitschrift fur Gefasskrankheiten.

[62]  G. Riemekasten,et al.  Systemic sclerosis - a systematic overview: part 1 - disease characteristics and classification, pathophysiologic concepts, and recommendations for diagnosis and surveillance. , 2011, VASA. Zeitschrift fur Gefasskrankheiten.

[63]  N. Said,et al.  Cardiovascular , Pulmonary and Renal Pathology Secreted Protein Acidic and Rich in Cysteine Deficiency Ameliorates Renal Inflammation and Fibrosis in Angiotensin Hypertension , 2007 .

[64]  D. Milewicz,et al.  Small interfering RNA inhibition of SPARC attenuates the profibrotic effect of transforming growth factor beta1 in cultured normal human fibroblasts. , 2005, Arthritis and rheumatism.

[65]  D. Milewicz,et al.  Small interfering RNA inhibition of SPARC attenuates the profibrotic effect of transforming growth factor β1 in cultured normal human fibroblasts , 2005 .

[66]  D. Arking,et al.  Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. , 2003, Nature genetics.

[67]  R. Ross,et al.  Inhibition of PDGF‐stimulated and matrix‐mediated proliferation of human vascular smooth muscle cells by SPARC is independent of changes in cell shape or cyclin‐dependent kinase inhibitors , 2002, Journal of cellular biochemistry.

[68]  A B West,et al.  Myofibroblasts: paracrine cells important in health and disease. , 2000, Transactions of the American Clinical and Climatological Association.

[69]  D. Powell,et al.  Powell, D. W. et al. Myofibroblasts. I. Paracrine cells important in health and disease. Am. J. Physiol. 277, C1-C9 , 1999 .